AstraZeneca Expands Cardiovascular Disease Prospects, Paying $100M for Oral Way to Drug Lp(a)

Cardiovascular disease drugs in development intended to reduce lipoprotein (a) are mostly injectable medications, though Eli Lilly also has both oral and injectable drugs in the clinic. AstraZeneca aims to hit that key protein target with an oral small molecule licensed from CSPC Pharmaceutical Group. The post AstraZeneca Expands Cardiovascular Disease Prospects, Paying $100M for…

Read More

Rethinking Security Among the Healthcare Workforce Crisis

As hospitals adapt to a landscape marked by staffing shortages, financial pressure and escalating safety concerns, security can no longer operate as an afterthought or a cost center. It must be a strategic enabler that protects the workforce, which in turn protects everyone else. The post Rethinking Security Among the Healthcare Workforce Crisis appeared first…

Read More